A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic… (NCT07115043) | Clinical Trial Compass
RecruitingPhase 1/2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
United States, Australia, Japan60 participantsStarted 2025-07-29
Plain-language summary
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR
. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.
. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is in Phase 1/2 and is primarily focused on finding a safe dose of AZD6750 before looking at whether it works — what does that mean for my personal risk if I were to consider joining, given that so little may be known yet about how this drug behaves in people?
2My cancer type is one of several listed in this study, including melanoma, triple negative breast cancer, and Merkel cell carcinoma among others — do you think my specific diagnosis and how advanced it is would make me a realistic candidate to discuss for a trial like this, or would standard treatments be a better first step?
3Since efficacy — meaning whether the drug actually shrinks tumors or helps — is only being measured in the later dose expansion part of the trial and not in the early dose escalation part, is there a chance I'd be enrolled in a phase where the main goal is safety testing rather than seeing a direct treatment benefit?
4AZD6750 appears to be a newer investigational drug with limited human data — are there any known signals from early research about what side effects or serious risks I should be prepared to discuss before even considering something like this?
5Given that this trial is actively recruiting across multiple tumor types, would you be able to help me understand what the visit schedule and monitoring demands might look like, and whether that would realistically fit my current health situation and daily life?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)
Timeframe: Measured from the informed consent until Day 90 post-last dose.
2
Efficacy- Part 2B only (dose expansion)
Timeframe: Measured every 6 weeks for 48 weeks and every 12 weeks thereafter from first dose until disease progression or death in the absence of disease progression(approximately 2 years)